Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vermillion holds off delisting with $20.5m from share sales:

This article was originally published in Clinica

Executive Summary

Diagnostics specialist Vermillion (formerly Ciphergen Biosystems) has received a timely financial boost - a windfall of $20.5m - from a private placement of approximately 24.4 million shares of common stock. The placement, made with a group of existing and new investors, will be used for general working capital and will be welcome relief to the Fremont, California-based firm, which was issued with a non-compliance letter from Nasdaq indicating a stockholders' equity below $2.5m; a market value of listed securities below $35m; or a net income of $500,000 for the previous fiscal year. Vermillion has until September 14 to regain compliance.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049598

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel